Abstract

Aberrant alternative splicing (AS) is increasingly linked to cancer; however, how AS contributes to cancer development still remains largely unknown. AS events (ASEs) are largely regulated by RNA-binding proteins (RBPs) whose ability can be modulated by a variety of genetic and epigenetic mechanisms. In this study, we used a computational framework to investigate the roles of transcription factors (TFs) on regulating RBP-AS interactions. A total of 6519 TF–RBP–AS triplets were identified, including 290 TFs, 175 RBPs, and 16 ASEs from TCGA–KIRC RNA sequencing data. TF function categories were defined according to correlation changes between RBP expression and their targeted ASEs. The results suggested that most TFs affected multiple targets, and six different classes of TF-mediated transcriptional dysregulations were identified. Then, regulatory networks were constructed for TF–RBP–AS triplets. Further pathway-enrichment analysis showed that these TFs and RBPs involved in triplets were enriched in a variety of pathways that were associated with cancer development and progression. Survival analysis showed that some triplets were highly associated with survival rates. These findings demonstrated that the integration of TFs into alternative splicing regulatory networks can help us in understanding the roles of alternative splicing in cancer.

Highlights

  • Published: 16 August 2021Renal cell carcinoma (RCC) is a common malignant tumor that, according to 2020 global cancer data released by the International Agency for Research on Cancer (IARC), accounts for 2.2% of all new cancer cases, with approximately 431,288 new cases and 179,368 deaths worldwide, and there will be approximately 73,587 new cases and 43,196 deaths in China.There are different types of RCC, and kidney renal clear cell carcinoma (KIRC) is the most common type of RCC, accounting for about 75% of adult RCC malignancies [1]

  • A computational method was previously developed to identify modulators whose expression levels could affect the relationship between the RNA-binding proteins (RBPs) and its target alternative splicing outcomes, and this only focused on target splicing outcomes of QKI that can be influenced by the expression level of modulators [15]

  • The results showed that the 4456 transcription factors (TFs)-RBP pairs, 1509 TF-AS events (ASEs) pairs, and 1280 RBPASE pairs involved in the triplet had 275 TF-RBP pairs, and 55 TF-ASE pairs and 93 RBPASE pairs overlapped with protein–protein interactions (PPIs), respectively, which is shown in Supplementary Figure S2

Read more

Summary

Introduction

Renal cell carcinoma (RCC) is a common malignant tumor that, according to 2020 global cancer data released by the International Agency for Research on Cancer (IARC), accounts for 2.2% of all new cancer cases, with approximately 431,288 new cases and 179,368 deaths worldwide, and there will be approximately 73,587 new cases and 43,196 deaths in China. There are different types of RCC, and kidney renal clear cell carcinoma (KIRC) is the most common type of RCC, accounting for about 75% of adult RCC malignancies [1]. Immune-checkpoint and targeted therapeutics inhibitors have changed the landscape of treatment for KIRC, most patients have never experienced significant clinical benefits [5,6]. It is essential to reveal the underlying molecular mechanisms of KIRC and find more powerful diagnostic biomarkers or therapeutic targets

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call